herein
report
discoveri
sar
novel
seri
sarscov
inhibitor
identifi
nih
molecular
librari
probe
product
center
network
mlpcn
addit
repres
second
probe
declar
collabor
effort
xray
structur
sarscov
bound
analog
highlight
uniqu
inducedfit
reorgan
bind
pocket
lead
first
submicromolar
noncoval
inhibitor
retain
singl
amid
bond
elsevi
ltd
right
reserv
coronavirus
cov
envelop
larg
plusstrand
rna
virus
associ
mild
sever
respiratori
symptom
includ
common
cold
sever
acquir
respiratori
syndrom
sar
cov
identifi
etiolog
agent
respons
global
pandem
sar
present
atyp
pneumonia
first
major
outbreak
led
progress
respiratori
failur
individu
death
juli
year
cooper
lead
nation
rigor
public
healthcar
campaign
fortun
success
control
outbreak
howev
reemerg
sarscov
consid
potenti
pandem
risk
new
strain
human
coronaviru
continu
identifi
sinc
two
addit
human
coronavirus
identifi
patient
virus
character
found
significantli
less
lethal
sarscov
recent
new
sarslik
viru
design
middl
east
respiratori
syndrom
coronaviru
merscov
identifi
patient
far
die
evid
persontoperson
transmiss
merscov
nearli
decad
later
possibl
anoth
sarslik
pandem
appear
even
palpabl
base
upon
lethal
properti
newli
identifi
mevhcov
strain
effect
vaccin
small
molecul
antivir
agent
prevent
treat
sarslik
infect
still
exist
thu
tailor
antivir
therapi
urgent
need
order
treat
potenti
futur
outbreak
sar
relat
human
coronavirus
sar
mer
coronavirus
encod
two
proteas
papainlik
proteas
plpro
proteas
genom
essenti
viral
replic
viral
polyprotein
cleav
three
uniqu
site
plpro
uniqu
site
initi
report
inhibitor
literatur
focus
peptidomimet
often
four
five
residu
length
bear
reactiv
warhead
group
aldehyd
halomethyl
keton
michael
acceptor
terminu
sever
demonstr
coval
interact
activ
site
residu
recent
major
effort
develop
nonpeptid
inhibitor
also
reli
warhead
base
design
strategi
fig
number
nonpeptid
inhibitor
achiev
submicromolar
activ
case
pyridyl
ester
potent
nanomolar
mechanismbas
enzym
inactiv
led
cell
base
inhibit
lm
sarscov
infect
vero
cell
recent
report
n
tertbutyl
narylamido
acetamid
fig
xray
complex
pdb
rare
exampl
noncoval
sarscov
inhibitor
moder
molecular
weight
good
enzym
antivir
inhibitori
activ
herein
describ
continu
effort
develop
potent
noncoval
inhibitor
base
upon
second
chemic
class
triazol
mlpcn
screen
campaign
fig
progress
lead
seri
second
gener
probe
fig
beyond
arriv
nm
inhibitor
propos
crystallographi
data
relat
triazol
seri
inhibit
via
novel
mechan
action
provid
new
direct
addit
noncoval
inhibitor
design
refin
use
design
express
construct
produc
postproteolyt
authent
dimer
screen
nih
molecular
librari
sampl
collect
k
compound
scripp
research
institut
molecular
screen
center
srimsc
undertaken
addit
diamid
acetamid
seri
repres
fig
relat
diamid
seri
repres
sid
fig
identifi
demonstr
ic
lm
good
select
versu
plpro
ic
lm
use
control
cysteineproteas
activ
fortun
quit
earli
chemistri
campaign
xray
crystal
structur
diamid
bound
determin
resolut
solvent
access
surfac
depict
activ
site
along
walley
stereo
view
key
contact
resid
hydrogen
bond
contact
depict
figur
interestingli
contrast
crystal
structur
accommod
substrat
subpocket
enzym
activesit
tradit
occupi
peptidomimet
diamid
engend
inducedfit
complex
result
new
surfac
dictat
larg
rearrang
residu
sidechain
induc
fit
accommod
syn
nmethyl
pyrrol
anilido
acetamid
moieti
inhibitor
within
subpocket
character
subpocket
respect
figur
schemat
illustr
inhibitoract
site
interact
orient
manner
similar
depict
figur
addit
p
p
p
p
group
inhibitor
partial
occupi
subpocket
termin
key
hydrogen
bond
interact
found
near
catalyt
site
benzotriazol
n
engag
key
interact
interatom
distanc
addit
backbon
nh
interact
evid
central
acetamid
oxygen
distanc
flexibl
diamid
scaffold
rotbon
coupl
observ
inducedfit
within
activ
site
present
ad
challeng
respect
silico
inhibitor
approach
thu
structureactivityrelationship
sar
studi
focus
initi
three
key
area
within
diamid
scaffold
benzotriazol
replac
altern
hydrogen
bond
acceptor
function
interact
acetamid
modif
within
p
p
region
minimum
pharmacophor
delet
studi
p
p
p
group
held
constant
investig
base
upon
ht
reconfirm
result
data
shown
nmethyl
pyrrol
replac
equipot
moieti
parallel
effort
obtain
crystal
structur
synthesi
first
gener
analog
survey
divers
benzotriazol
unit
initi
use
modifi
version
strategi
scheme
allow
late
stage
azol
introduct
thu
ugi
reaction
use
tbutyl
isocyanid
chloroacet
acid
n
acetamid
proceed
smoothli
give
chlorid
could
isol
good
yield
chromatographi
displac
chlorid
azol
nh
heterocycl
provid
altern
displac
sodium
azid
subsequ
huisgen
cycloaddit
reaction
appropri
acetylen
furnish
good
overal
yield
synthesi
p
p
amid
analog
within
elabor
diamid
similarli
prepar
ugi
reaction
use
bocprotect
amino
anilin
scheme
amin
compon
deprotect
use
trifluoroacet
gave
anilin
react
varieti
carboxyl
acid
deriv
hatu
coupl
condit
react
acid
chlorid
sufonyl
chlorid
presenc
tea
give
final
exampl
synthesi
p
truncat
analog
began
reduct
amin
use
either
bocprotect
amino
anilin
give
intermedi
good
yield
amid
coupl
hatu
use
acid
instal
requisit
p
group
afford
initi
effort
focus
prepar
ident
amid
librari
prepar
elabor
seri
scheme
readili
accomplish
bocdeprotect
follow
amid
coupl
acylationsulfonyl
gave
subsequ
synthesi
seri
biaryl
amid
replac
commenc
use
suzuki
crosscoupl
varieti
boron
acid
afford
target
molecul
sar
p
replac
fig
indic
strict
requir
unit
benzimidazol
deriv
uniformli
inact
sinc
n
nitrogen
appear
involv
hydrogen
bond
somewhat
surpris
toler
sinc
imidazol
potenti
maintain
n
hydrogen
bond
interact
howev
within
structur
catalyt
residu
locat
within
n
nitrogen
indic
potenti
weak
hydrogen
bond
andor
dipoledipol
stabil
interact
potenti
interact
may
perhap
respons
prefer
interestingli
toler
ic
lm
suggest
addit
avenu
optim
accommod
phenyl
moieti
within
activ
site
subpocket
entir
clear
time
base
structur
predict
within
close
proxim
unsubstitut
triazol
trimethyl
silyl
triazol
inact
demonstr
import
maintain
proper
aromat
ring
subpocket
amid
librari
fig
within
elabor
diamid
seri
display
rang
potenc
moder
micromolar
activ
compar
ht
hit
weakli
activ
inact
cyclic
acycl
acetamid
congen
relat
ht
lead
show
consist
activ
lm
branch
ipropyl
deriv
cyclobutyl
amid
greatest
activ
lm
modif
sulfonamid
result
threefold
loss
inhibit
rel
acetamid
smaller
cyclopropyl
larger
cyclohexyl
cyclic
amid
gener
result
loss
inhibit
incorpor
steric
hinder
tbutyl
amid
also
led
modest
threefold
loss
activ
lastli
aromat
heteroaromat
amid
addit
isobutyl
carbam
weak
inact
inhibitor
collect
data
appear
consist
structur
wherebi
short
helixloophelix
motif
proxim
bturn
element
defin
edg
pocket
minim
volum
larger
group
beyond
acetamid
limit
success
studi
turn
p
truncat
potenti
identifi
minimum
pharmacophor
reduc
overal
mw
improv
ligand
effici
le
examin
p
group
within
structur
suggest
group
unfavor
solvent
expos
rel
tbutylamid
interact
found
within
structur
initi
effort
led
tabl
gratifyingli
truncat
amid
prove
compar
activ
versu
elabor
diamid
counterpart
fig
see
g
vs
tabl
see
interestingli
truncat
seri
appear
better
toler
larger
substitu
perhap
suggest
addit
chang
shape
activ
site
within
subpocket
exampl
cyclohexyl
amid
found
weak
inhibitor
similarli
carbam
moder
inhibitori
activ
lm
relat
counterpart
fig
inact
stage
project
effort
focus
p
truncat
analog
bear
put
interact
elect
character
probe
declar
fig
rel
probe
equipot
diamid
prove
offer
improv
sever
area
fig
sar
inhibitor
amu
lower
mw
mw
rel
moder
ligand
effici
le
delet
lipophil
p
group
reduc
c
log
p
order
magnitud
c
log
p
thu
greatli
improv
ligandefficiencydepend
lipophil
lelp
versu
probe
molecul
evalu
inhous
vitro
dmpk
panel
includ
plasma
protein
bind
enzym
inhibit
intrins
clearanc
use
liver
microsom
fig
possess
good
free
fraction
superior
improv
human
rat
fraction
unbound
respect
howev
intrins
clearanc
cl
hep
normal
liver
blood
flow
q
h
mlminkg
q
r
mlminkg
indic
predict
highli
clear
possess
modest
enzym
inhibit
maintain
lm
activ
across
four
major
cyp
enzym
fig
probe
found
highli
select
eurofin
leadprofil
screen
modest
activ
melatonin
mt
receptor
radioligand
bind
assay
base
absenc
key
hydrogen
bond
interact
p
p
amid
activ
site
addit
poor
metabol
instabl
cyp
profil
opt
explor
divers
amid
replac
mean
improv
metabol
stabil
activ
inhibitori
potenc
initi
effort
identifi
repres
nmethyl
nbenzyl
anilin
potenc
compar
probe
lack
activ
benzamid
versu
reduc
benzylamin
strike
indic
enhanc
flexibl
nbenzyl
group
permit
product
interact
occur
previous
aromat
amid
toler
see
fig
subsequ
survey
biaryl
explor
tabl
basi
xray
target
heterocycl
mean
potenti
engag
sidechain
interact
hydroxyl
group
modif
afford
inhibitor
micromolar
activ
case
submicromolar
activ
ic
nm
unexpectedli
parent
simpl
phenyl
biaryl
prove
major
impact
activ
increas
rel
inhibitor
repres
first
nm
inhibitor
seri
knowledg
one
potent
nonwarhead
base
sar
inhibitor
date
time
inhibitor
rel
unoptim
thu
current
effort
focus
target
biaryl
congen
understand
dmpk
cellular
activ
well
potenti
broad
spectrum
activ
coronaviru
strain
includ
merscov
summari
describ
identif
bind
orient
interact
second
class
diamid
sar
inhibitor
culmin
probe
subsequ
improv
inhibitor
possess
le
lelp
approach
xray
crystal
structur
ht
hit
bound
instrument
guid
optim
inducedfit
inhibitor
complex
illustr
challeng
diverg
sar
limit
virtual
base
screen
four
compon
ugi
reaction
util
rapidli
gener
sar
put
p
p
p
subgroup
importantli
p
truncat
possibl
triazol
seri
inhibitor
allow
signific
mw
reduct
without
diminish
potenc
collabor
effort
laboratori
continu
toward
identif
activ
inhibitor
within
truncat
biaryl
class
integr
effort
dmpk
assess
continu
order
improv
intrins
clearanc
diminish
activ
issu
address
within
seri
prior
vivo
proofofmechan
studi
mlpcn
probe
freeli
avail
upon
request
